Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:603858'
s EV-to-FCF Range Over the Past 10 Years
Min: -53.55 Med: 20.38 Max: 259.25
Current: 54.44
During the past 13 years, the highest EV-to-FCF of Shandong Buchang Pharmaceuticals Co was 259.25. The lowest was -53.55. And the median was 20.38.
SHSE:603858's EV-to-FCF is ranked worse than 76.18% of 571
companies
in the Drug Manufacturers industry
Industry Median: 21.2
vs SHSE:603858: 54.44
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shandong Buchang Pharmaceuticals Co (SHSE:603858) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shandong Buchang Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
Shandong Buchang Pharmaceuticals Co's share price for today is ¥15.66.
Shandong Buchang Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.357.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shandong Buchang Pharmaceuticals Co EV-to-FCF Related Terms
Shandong Buchang Pharmaceuticals Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Buchang Pharmaceuticals Co EV-to-FCF Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Buchang Pharmaceuticals Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Buchang Pharmaceuticals Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shandong Buchang Pharmaceuticals Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Shandong Buchang Pharmaceuticals Co's EV-to-FCF falls into.
Shandong Buchang Pharmaceuticals Co's current Enterprise Value is ¥18,608 Mil.
Shandong Buchang Pharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥342 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Buchang Pharmaceuticals Co (SHSE:603858) has a EV-to-FCF of 54.44 as of Aug. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shandong Buchang Pharmaceuticals Co and its competitors. This is 167% above median its historical median of 20.38. According to the industry distribution chart, Shandong Buchang Pharmaceuticals Co ranks #435 out of 571 companies in the Drug Manufacturers industry, placing it in the top 76.2%.
Is Shandong Buchang Pharmaceuticals Co's EV-to-FCF too high?
Shandong Buchang Pharmaceuticals Co's current EV-to-FCF of 54.44 is 167% above median its 10-year median of 20.38. The Drug Manufacturers industry median EV-to-FCF is 21.20. Shandong Buchang Pharmaceuticals Co's value of 54.44 is 156.8% above this industry median. Based on the distribution chart, Shandong Buchang Pharmaceuticals Co ranks #435 out of 571 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shandong Buchang Pharmaceuticals Co has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shandong Buchang Pharmaceuticals Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shandong Buchang Pharmaceuticals Co ranks #435 out of 571 companies for EV-to-FCF. This places Shandong Buchang Pharmaceuticals Co in the lower half of its industry. The industry median EV-to-FCF is 21.20. Shandong Buchang Pharmaceuticals Co's value of 54.44 is 156.8% above this benchmark. While the company's 10-year median is 20.38 vs. the industry median of 21.20, Shandong Buchang Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.20, based on 571 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Buchang Pharmaceuticals Co's current EV-to-FCF of 54.44 is 156.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shandong Buchang Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Buchang Pharmaceuticals Co's current EV-to-FCF is 54.44, which is 167% above median its own 10-year median of 20.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Buchang Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Buchang Pharmaceuticals Co (SHSE:603858) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.94, compared to a current price of ¥15.66 — trading 1.8% below its estimated fair value. The current EV-to-FCF is 54.44, which is 167% above median its 10-year median of 20.38 and 156.8% above the Drug Manufacturers industry median of 21.20. Shandong Buchang Pharmaceuticals Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shandong Buchang Pharmaceuticals Co (SHSE:603858), the current EV-to-FCF is 54.44 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Buchang Pharmaceuticals Co (SHSE:603858) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Buchang Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥15.66 is trading 1.8% below its estimated GF Value™ of ¥15.94.
GuruFocus considers Shandong Buchang Pharmaceuticals Co to be Fairly Valued.
Key valuation signals for SHSE:603858:
EV-to-FCF: 54.44 (167% above median its 10-year median of 20.38)
GF Value™: ¥15.94 vs. price of ¥15.66 (1.8% below fair value)
Industry Position: 156.8% above the Drug Manufacturers median (#435 of 571)
No single metric tells the full story. See the SHSE:603858 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603858 has been successfully added to your 
